Generic Daclatasvir

Introduction

Daclatasvir is an oral antiviral medication indicated for the treatment of chronic hepatitis C virus (HCV) infection. It belongs to the class of direct‑acting antiviral agents (DAAs) that target specific steps in the HCV life cycle. In Kingdom, Daclatasvir is used in combination regimens to achieve sustained virologic response (SVR), which is tantamount to a cure. The drug is manufactured by Bristol‑Myers Squibb under the brand name Daklinza and is also available as a generic product containing the identical active compound, Daclatasvir.

What is Daclatasvir?

Daclatasvir is the generic version of Daklinza, containing the same active compound Daclatasvir. It is a small‑molecule inhibitor of the HCV non‑structural protein 5A (NS5A), a viral co‑factor essential for RNA replication and assembly of new virions. The generic formulation is produced by licensed manufacturers that fulfil the same stringent quality standards required by the European Medicines Agency (EMA). Our online pharmacy provides this generic alternative as a cost‑effective treatment option for patients who meet the clinical criteria for Daclatasvir‑based therapy.

How Daclatasvir Works

The HCV genome encodes several non‑structural proteins that cooperate to replicate viral RNA. NS5A is a phosphoprotein that orchestrates the formation of the replication complex and the release of infectious particles. Daclatasvir binds to a highly conserved region of NS5A, inducing a conformational change that blocks its interaction with host and viral factors. This inhibition halts RNA synthesis, prevents viral assembly, and reduces viral load rapidly. Pharmacokinetic data show that peak plasma concentrations are reached within 2–4 hours after oral administration, and the drug has a terminal half‑life of approximately 12–15 hours, allowing once‑daily dosing. Daclatasvir is primarily eliminated via hepatic metabolism, with minimal renal excretion, which is relevant for patients with kidney disease.

Conditions Treated with Daclatasvir

• Chronic Hepatitis C Virus (HCV) Infection – Daclatasvir is approved in the UK for use in combination with other DAAs such as sofosbuvir, grazoprevir, or velpatasvir. The regimen is indicated for all HCV genotypes (1‑6) when paired with an appropriate partner drug, including patients with compensated cirrhosis.

• HCV Genotype‑Specific Regimens – For genotype 1, 2, 3, 4, 5, and 6 infections, Daclatasvir‑based combinations have demonstrated SVR rates exceeding 90 % in phase III clinical trials (e.g., the ALLY‑3, GARNET, and ENDURANCE studies).

• Patients with Prior Treatment Failure – Individuals who have not achieved SVR with earlier interferon‑based regimens or other DAAs may benefit from Daclatasvir as part of a rescue protocol, particularly when resistance‑associated substitutions (RAS) are present.

In the United Kingdom, approximately 200,000 individuals are estimated to have chronic HCV infection, with a substantial proportion unaware of their status. Daclatasvir contributes to the National Health Service’s elimination target of reducing HCV prevalence by 90 % by 203.

Who is Daclatasvir For?

• Adults with Confirmed Chronic HCV – The medication is indicated for patients aged 18 years and older who have documented HCV RNA positivity.

• All HCV Genotypes – When combined with a suitable partner drug, Daclatasvir provides pan‑genotypic coverage, making it suitable for patients whose genotype is unknown or who have mixed infections.

• Patients with Compensated Cirrhosis – Clinical data support the safety and efficacy of Daclatasvir‑based regimens in individuals with Child‑Pugh A cirrhosis.

• Individuals Who Are Interferon‑Ineligible or Intolerant – Because Daclatasvir is oral and interferon‑free, it is appropriate for patients who cannot tolerate the side‑effects of interferon or ribavirin.

• Those With Specific Resistance Profiles – In cases where NS5A resistance‑associated substitutions are detected, dose adjustments or the addition of a second NS5A inhibitor may be recommended; clinicians evaluate each scenario individually.

• Contra‑indications – Daclatasvir should not be used in patients with known hypersensitivity to the drug or any of its excipients, and caution is advised in individuals receiving strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) because they markedly reduce Daclatasvir exposure.

Risks, Side Effects, and Interactions

Common

• Fatigue – Reported in up to 20 % of patients; generally mild and transient.
• Headache – One of most frequent complaints, often manageable without medication.
• Nausea – Mild gastrointestinal upset occurring in roughly 10‑15 % of users.

Rare

• Elevated Liver Enzymes – Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) rises above the upper limit of normal in < 2 % of cases; monitoring is advised, especially in patients with pre‑existing liver disease.
• Pruritus – Itching without rash appears in a small minority and typically resolves spontaneously.

Serious

• Severe Hepatic Decompensation – Rare cases of acute liver failure have been reported when Daclatasvir is used in patients with decompensated cirrhosis (Child‑Pugh B or C). Immediate discontinuation and specialist assessment are required.
• Cardiovascular Events – Isolated reports of arrhythmia and myocardial infarction exist, but causality has not been established; patients with uncontrolled cardiac disease should be evaluated closely.
• Hypersensitivity Reactions – Anaphylaxis or severe skin reactions (e.g., Stevens‑Johnson syndrome) are extremely uncommon but necessitate urgent medical attention.

Drug‑Drug Interactions

• Strong CYP3A4 Inducers – Rifampicin, St. John’s wort, carbamazepine, phenobarbital, and phenytoin can lower Daclatasvir plasma concentrations, reducing efficacy. Avoid co‑administration or adjust dosing as guided by a specialist.

• Strong CYP3A4 Inhibitors – Ketoconazole, itraconazole, ritonavir-boosted protease inhibitors increase Daclatasvir exposure; dose reduction (typically to 30 mg once daily) may be required.

• P‑glycoprotein (P‑gp) Modulators – Drugs such as amiodarone or verapamil can affect Daclatasvir absorption; monitoring is advisable.

• Co‑administered DAAs – Most approved combination regimens have been studied extensively; however, unapproved mixtures should be avoided to prevent resistance development.

Practical Use: Dosing, Missed Dose, Overdose

• Standard Dosing – The usual adult dose of Daclatasvir is 60 mg (one tablet) taken orally once daily, with or without food. Dose adjustments are necessary only when the patient receives a strong CYP3A4 inhibitor, in which case the dose is reduced to 30 mg once daily.

• Treatment Duration – When paired with sofosbuvir, therapy typically lasts 12 weeks for most genotypes; shorter courses (8 weeks) may be appropriate in selected non‑cirrhotic patients with low baseline viral load.

• Missed Dose – If a dose is forgotten, the patient should take it as soon as they remember, provided it is at least 12 hours before the next scheduled dose. If the next dose is imminent, skip the missed tablet and resume the regular schedule; double‑dosing is not recommended.

• Overdose – Acute overdose of Daclatasvir is rare. Symptoms may include nausea, vomiting, and dizziness. Patients should seek immediate medical attention; supportive care is the mainstay of management.

• Food and Alcohol – Daclatasvir may be taken with meals; high‑fat meals do not significantly alter exposure. Moderate alcohol consumption is permissible, but patients with advanced liver disease should limit intake as advised by their clinician.

• Renal and Hepatic Impairment – No dose adjustment is required for mild to moderate renal dysfunction. In severe hepatic impairment (Child‑Pugh B/C), Daclatasvir is contraindicated due to the risk of decompensation.

Buying Daclatasvir from Our Online Pharmacy

Patients in the United Kingdom who encounter barriers to accessing Daclatasvir through conventional channels can obtain the medication from our online pharmacy.

• Affordable Pricing – We source the generic product directly from EMA‑registered manufacturers, enabling prices that are close to the wholesale cost while maintaining high quality.

• Verified Quality – Every batch is verified for potency, purity, and compliance with Good Manufacturing Practice (GMP). Independent laboratory testing confirms that the generic contains the identical active ingredient as the brand‑name Daklinza.

• Guaranteed Delivery – Orders are dispatched discreetly in unmarked packaging. Standard UK delivery arrives within 7 days, and an express option is available for delivery in 3–4 days. International shipments are performed via reliable airmail, typically arriving within 2‑3 weeks.

• Online‑Only Access – As a pharmacy broker service, we collaborate with licensed overseas pharmacies that hold valid certifications. This model expands the availability of essential medicines that may be scarce or delayed in the UK market.

• Privacy‑Focused Service – All personal data are encrypted, and billing statements use neutral descriptions to protect patient confidentiality.

Our online pharmacy serves individuals who have limited insurance coverage, encounter supply shortages, or simply seek a more cost‑effective alternative without compromising safety.

FAQ

• Is Daclatasvir available in both brand‑name and generic forms in the UK?
  Yes. The medication is marketed as the brand‑name Daklinza and is also sold as a generic containing the same active compound, Daclatasvir. The generic version offers a lower‑cost option while meeting the same regulatory standards.

• Does Daclatasvir require refrigeration or special storage conditions?
  No refrigeration is needed. the tablets at a controlled room temperature, between 15 °C and 30 °C, away from direct sunlight, moisture, and heat sources such as radiators or kitchen ovens.

• What does the tablet of Daclatasvir look like?
  The generic tablet is typically a white, film‑coated tablet bearing the imprint “DACL 60 mg” or a similar identifier, depending on the manufacturer. The brand‑name Daklinza tablets are also white, film‑coated, with “D” and “K” markings.

• Can I travel internationally with Daclatasvir, and are there any customs considerations?
  Yes, you may travel with a personal supply of Daclatasvir for up to 90 days. Carry the original packaging and a copy of the prescription or a doctor’s letter. UK customs permits personal import of up to a three‑month supply for personal use, provided it is for a legitimate medical purpose.

• Are there any known differences in the formulation of Daclatasvir between regions (e.g., EU vs. US)?
  The active ingredient is identical worldwide. However, some regional formulations may contain different inactive excipients, such as varying film‑coating polymers. These differences are not clinically significant but may affect patients with rare excipient sensitivities.

• What is the history behind the development of Daclatasvir?
  Daclatasvir was discovered by researchers at Bristol‑Myers Squibb and entered clinical development in the early 201s. It received EMA approval in 2015 after pivotal phase III trials demonstrated high cure rates across multiple HCV genotypes, leading to its inclusion in national treatment guidelines.

• How does Daclatasvir compare with first‑generation HCV treatments like interferon?
  Unlike interferon, which requires subcutaneous injections and is associated with flu‑like symptoms, depression, and hematologic toxicity, Daclatasvir is an oral, interferon‑free agent with a much more favorable safety profile and shorter treatment duration (8‑12 weeks versus up to 48 weeks).

• Will taking Daclatasvir affect routine blood tests for liver function?
  Daclatasvir itself does not significantly alter liver enzyme levels; however, clinicians routinely monitor ALT, AST, bilirubin, and albumin during therapy to assess both disease response and any potential hepatic adverse events.

• Is there any risk of Daclatasvir causing a false‑positive drug test?
  No. Daclatasvir is not recognized by standard occupational or forensic drug‑screening panels and does not produce metabolites that trigger false‑positive results for commonly tested substances.

• What should I do if I develop a rash while on Daclatasvir?
  A mild rash is usually self‑limiting. Apply a soothing emollient and monitor for progression. If the rash becomes widespread, blistering, or is accompanied by fever, seek immediate medical evaluation as it may represent a serious hypersensitivity reaction.

Glossary

NS5A (Non‑structural protein 5A)

A viral protein essential for hepatitis C virus RNA replication and assembly of new viral particles; the primary target of Daclatasvir.

Sustained Virologic Response (SVR)

The absence of detectable HCV RNA in the blood 12 weeks after completing therapy, considered a functional cure.

CYP3A4 (Cytochrome P450 3A4)

An enzyme in the liver responsible for metabolising many drugs; strong inducers or inhibitors of CYP3A4 can alter Daclatasvir levels.

Child‑Pugh Classification

A scoring system used to assess the severity of liver disease, particularly cirrhosis, based on clinical and laboratory parameters.

⚠️ Disclaimer

The information provided about Daclatasvir is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Daclatasvir for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.